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Abstract
Background: Glucose fluctuations including robust postprandial hyperglycemia are a risk for promoting
atherosclerosis and diabetic complications. The a-glucosidase inhibitors and the dipeptidyl peptidase-4 (DPP-4)
inhibitors have been found to effectively decrease postprandial hyperglycemia independently. Therefore, glycemic
control with the combination of these drugs is warranted.
Methods: Continuous glucose monitoring (CGM) was performed for 3 patients with type 2 diabetes and 1 control
subject from the beginning to the end of the study. Medications were not administered to any of the subjects on
the first day of the study. From the second day to the end of study (days 2-5), the subjects received miglitol (150
mg per day) and on days 4 and 5, sitagliptin (50 mg per day) was added to the treatment regimen. On the first,
third, and fifth days of the study, blood was drawn at 0, 30, 60, 120, 180, and 240 min after breakfast for
measurements of serum insulin, 1,5-anhydroglucitol (1,5-AG), plasma glucagon, glucagon-like peptide-1 (GLP-1), and
glucose-dependent insulinotropic peptide (GIP).
Results: Measurements of CGM and 1,5-AG levels showed that miglitol attenuated the escalation and fluctuation
of glucose levels, and this was even more pronounced with the combination of miglitol and sitagliptin. The
patterns of insulin secretion and glucagon secretion with miglitol alone or with a combination of miglitol and
sitagliptin were various in the study subjects. Miglitol alone enhanced the release of GLP-1 in 1 patient with type 2
diabetes and the control subject, whereas the combination of miglitol and sitagliptin increased GLP-1 levels to
varying degrees in all the subjects. Except for 1 subject, none of the subjects showed any change in GIP levels
after the addition of sitagliptin, compared to the administration of miglitol alone.
Conclusions: In conclusion, CGM measurements revealed that a combination of the a-GI miglitol and the DPP-4
inhibitor sitagliptin effectively reduced postprandial glucose fluctuation and stabilized blood glucose levels.
Completely different response patterns of insulin, glucagon, GLP-1, and GIP were observed among the study
subjects with either medication alone or in combination, suggesting that individual hormone-dependent glycemic
responses to the a-GI and DPP-4 inhibitors are complicated and multifactorial.
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Introduction
Patients with type 2 diabetes mellitus are at an increased
risk for cardiovascular disease [1,2]. Recent studies have
indicated that glycemic variability plays a role in the
pathogenesis of atherosclerosis, because acute fluctua-
tions of glucose levels lead to oxidative stress [3-5] and
have more deleterious effects on the development of car-
diovascular complications in patients with diabetes than
sustained hyperglycemia [3-7]. Therefore, improved clini-
cal outcomes in patients with diabetes may be related to
the effort to reduce the fluctuations of glucose levels [8].
a-Glucosidase inhibitors (a-GIs), a promising class of
glycemic control agents delay the absorbance of carbo-
hydrates and decrease both postprandial hyperglycemia
and hyperinsulinemia. These agents inhibit the activity
of a-glucosidase, which is a membrane-bound enzyme
located in the epithelium of the small intestine and is
involved in the digestion of carbohydrates. By competi-
tively inhibiting the breakdown of carbohydrates, a-GIs
delay the absorption of digested carbohydrates from the
small intestine and thus lower both postprandial glucose
and insulin levels [9]. Results of the STOP-NIDDM ran-
domized trial showed that the a-GI acarbose could be
used, either as an alternative or in addition to a change
in lifestyle, to delay the development of type 2 diabetes
in patients with impaired glucose tolerance [10].
Another promising class of therapeutic targets for
decreasing glucose fluctuations is the incretin-related
agents. There has been a recent increased appreciation
for the role of incretins in controlling the postprandial
metabolic milieu [11]. The incretins, glucagon-like pep-
tide-1 (GLP-1) and glucose-dependent insulinotropic
polypeptide (GIP) are released from enteroendocrine
cells and enhance insulin secretion [12,13]. Incretins are
rapidly inactivated by the enzyme dipeptidyl peptidase-4
(DPP-4), resulting in a very short half-life. DPP-4 inhibi-
tors, such as sitagliptin, increase active GLP-1 and GIP
levels by inhibiting DPP-4 enzymatic activity and
improve hyperglycemia in a glucose-dependent fashion
by increasing serum insulin and decreasing serum gluca-
gon levels in diabetic patients [14]. In addition, the a-
GIs reportedly enhance GLP-1 responses and reduce
total GIP responses [15-18]. The combination of an a-
GI and a DPP-4 inhibitor has been reported to increase
active GLP-1 levels and additively improve glucose toler-
ance in mice, compared to DPP-4 inhibitor alone [19].
Considering the different but complementary mechan-
isms of action by which a-GIs and DPP-4 inhibitors
lower glucose levels and increase GLP-1 action, a com-
bination therapy with these agents may provide a valu-
able means of treating diabetes [20].
The aim of the present study is to evaluate the efficacy
of miglitol alone and in combination with sitagliptin on
changes in blood glucose levels, precisely evaluated by a
continuous glucose-monitoring system (CGMS) [21-23],
and determine the effect of these agents on changes in
insulin, 1,5-anhydroglucitol (1,5 AG), glucagon, GLP-1,
and GIP levels in subjects with type 2 diabetes.
Methods
Subjects
The baseline characteristics of the 3 Japanese patients with
type 2 diabetes who were treated with diet therapy alone
or with oral hypoglycemic agents other than a-GIs or
DPP-4 inhibitors, and 1 Japanese female control subject
are summarized in Table 1. The value for haemoglobin
A1c (HbA1c) (%) was converted to National Glycohemo-
globin Standardization Program (NGSP) levels by using
the formula: HbA1c (%)(NGSP) = HbA1c [Japan Diabetic
Society (JDS)] (%) + 0.4%, considering the relational
expression of HbA1c (JDS) (%) measured by the previous
Japanese standard substance and measurement methods
[24]. All anti-diabetic drugs were washed out for 5 days
before each experimental day. The study protocol was
approved by the Ethics Committee of the National Center
for Global Health and Medicine (NCGM), and written
informed consent was obtained from each study subject.
The study was conducted in accordance with the ethical
principles stated in the Declaration of Helsinki.
Procedure
Cgms
The patients were admitted to a diabetic ward at the
NCGM and equipped with a CGMS device (CGMS-
GOLD; Medtronic MiniMed, Northridge, CA, USA). The
subjects were monitored for 3 days before the study and
until the end of the 5-day study period. The CGMS soft
sensor was changed at the proper times according to the
manufacturer’s instructions. Glucose levels measured with
a self-monitoring blood glucose (SMBG) device (Nipro
Stat Strip XP; Nipro, Japan) were checked at least 4 times
per day for calibration of the CGMS. The recorded data
were analyzed with CGMS Solutions software.
Breakfast
The calories of each breakfast through the study period
were determined, considering age and body mass index
Table 1 Subject characteristics
Case 1 Case 2 Case 3 Control
Age (yr) 67 69 76 48
Gender Female Male Male Female
BMI (kg/m2) 26.9 26.5 24.1 22.2
Diabetes duration (yr) 5 11 1 none
Treatment SU SU + Met Diet only none
Hb A1c (%) 7.1 7.3 7.0 5.3
Abbreviations: BMI, body mass index; SU, sulfonyl urea; Met, metformin.
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(BMI) of each patient and the control subject. For
example, the mean calories for patients in case 1, 2, 3,
and the control subject were 310, 413, 400, and 470
kcal, respectively.
Sample collection and analysis
On the first day of the study, after an overnight fast for
14 h, an intravenous line was inserted into 1 forearm
vein and flushed with sterile 0.9% NaCl solution for
repeated blood sampling. Blood was drawn at 0, 30, 60,
120, 180, and 240 min after breakfast (the meal was
ingested within 10-15 min) for measurements of serum
insulin, 1,5-AG, plasma glucagon, GLP-1, and GIP.
Blood samples were immediately cooled and centrifuged
at 4°C, and plasma was stored at -20°C until analysis.
Blood samples for determination of active GLP-1 were
collected into chilled BD P700 tubes containing spray-
dried K2EDTA anticoagulant and proprietary DPP-4
protease inhibitor (Becton Dickinson, Franklin Lakes,
NJ, USA), and the GLP-1 concentrations were measured
using an enzyme-linked immunosorbent assay (ELISA)
kit (Millipore Corporation, Billerica, MA, USA). Plasma
concentrations of amidated GLP-1 (7-36) and (7-37)
were measured using an antibody that is highly specific
for the N-terminus of GLP-1 and does not react with
GLP-1 (9-36), GLP-2, or glucagon. The detection limit
of the ELISA was 2 pmol/l, with an intra-assay coeffi-
cient of variation (CV) of 2.6%-6.0% and interassay CV
of 7.1%-9.8%. Total GIP was measured using a human
GIP ELISA kit (Millipore Corporation). This kit has
100% cross reactivity to human GIP (1-42) and GIP (3-
42), with a detection limit of 1.8 pmol/l, an intraassay
CV of 4.8%-6.3%, and an interassay CV of 2.2%-5.0%.
Serum insulin was measured using a chemiluminescent
enzyme immunoassay (CLEIA). Blood samples for gluca-
gon measurements were collected in tubes containing
EDTA-2Na plus aprotinin and analyzed with a double-
antibody radioimmunoassay. Serum 1,5 AG was mea-
sured using an enzymatic method (Nippon Kayaku,
Tokyo, Japan). All sample measurements were per-
formed at SRL, Inc. (Tokyo, Japan). Areas under the
curve (AUC) values for these hormones after meal
ingestion were calculated using the trapezoidal rule.
Medications
From the second day to the end of the study period, the
subjects were prescribed miglitol (50 mg), 3 tablets per
day just before every meal. From day 4 through day 5,
the subjects were also prescribed sitagliptin (50 mg), 1
tablet per day before breakfast. Blood sampling was also
performed on the third day and the fifth day of the
study. The sampling methods and timing were identical
for each blood sampling period.
Results
During the 5-day study period, the subjects experienced
no gastrointestinal symptoms with the study medica-
tions, and CGM was completed without any problems.
Figure 1 shows that the escalation and fluctuation of
glucose levels measured by CGM after administration of
miglitol alone were attenuated. This attenuation of
blood glucose levels was even more pronounced with
the combination of miglitol and sitagliptin. The accuracy
of these measurements was reflected in the mean and
standard deviation (SD) values of CGM measurements,
as well as changes in 1,5-AG levels (Table 2).
The time-course levels of glucose (CGM), insulin,
insulin to glucose ratio, glucagon, active GLP-1, total
GIP, and AUC values for these hormones up to 4 h
after meal ingestion are summarized in Figures 2, 3, 4
and 5 and Table 3. Compared to no medication, miglitol
administration attenuated the postprandial increments
in plasma insulin levels in all the subjects, including the
control subjects. In all subjects except case 3, similar
patterns of insulin secretion were seen in insulin to glu-
cose ratios. When sitagliptin was coadministered with
miglitol, further attenuation of postprandial increment
in insulin was observed in case 3 and the control sub-
ject; no remarkable changes in insulin levels were
observed in the other subjects. These results were also
confirmed by the changes in insulin to glucose ratio.
Administration of miglitol had no observable effect on
blood glucagon levels after meal ingestion in any sub-
ject. Similarly, when sitagliptin was added to miglitol, no
remarkable changes in glucagon levels were observed in
any of the subjects. Compared to no medication, migli-
tol administration resulted in slightly higher GLP-1
levels in the patient in case 3 and the control subject,
but not in the patients in cases 1 and 2. After sitagliptin
was coadministered with miglitol, remarkable incremen-
tal increases in GLP-1 levels were observed in all the
study subjects. Compared to no medication, miglitol
administration resulted in decreased GIP levels in
patients in cases 1 and 2 and the control subject, but
not in the patient in case 3. When sitagliptin was added
to miglitol, the patient in case 3 and the control subject
showed further decreases in GIP levels, which was not
observed in the other 2 subjects with diabetes. Com-
pared to no medication, all the subjects showed sup-
pressed GIP levels when miglitol and sitagliptin were
coadministered.
Discussion
The results of the present study showed that an admin-
istration of miglitol alone had beneficial effects on post-
prandial hyperglycemia, and these effects were even
more pronounced when sitagliptin was coadministered
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with miglitol. This beneficial effect on hyperglycemia
was demonstrated precisely by the mean ± SD values of
the glucose levels monitored with CGMS together with
the 1,5-AG levels that reflect glycemic excursions, often
in the postprandial state, more robustly than HbA1c or
fructosamine measurements [25,26].
In a separate study, Lee et al. reported that miglitol
induced enhanced and prolonged GLP-1 release and
suppressed plasma GIP secretion after ingestion of an
ordinary meal in the case of obese patients with diabetes
and glycemic control [17]. These results were supported
by the results of a study by Narita et al. who showed
consistent enhancing effects of miglitol on GLP-1
responses to a mixed meal in patients with type 2 dia-
betes [15,18]. These investigators also showed that in
response to administration of miglitol, plasma glucose,
insulin, and GIP levels significantly decreased during the
early postprandial phase, and both active and total GLP-
1 levels were significantly higher during the late post-
prandial phase. To confirm these results, we also mea-




no medication miglitol miglitol and sitagliptin
Control 
Figure 1 The results of CGM for patients in cases 1 to 3, and the control subject with the conditions of no medication, miglitol alone,
and coadministration of miglitol and sitagliptin.
Table 2 24 hours glucose levels measured by CGM and
1,5-AG levels
Case 1 Case 2 Case 3
Glucose (mg/dl) (Average ± SD)
no medication 120 ± 34 193 ± 44 161 ± 55
miglitol 131 ± 19 164 ± 24 131 ± 43
miglitol + sitagliptin 120 ± 14 156 ± 20 151 ± 21
1,5-AG (μg/ml)
no medication 8.5 5.9 17.6
miglitol 8.2 6.8 17.7
miglitol + sitagliptin 8.8 7.9 17.9
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administration of the medications. With miglitol admin-
istration, all the subjects exhibited an attenuated post-
prandial increment in insulin, which may be explained
by an induced decrease in blood glucose levels. When
we added sitagliptin to miglitol, we theoretically
expected a postprandial increment in insulin levels
owing to the effect of this drug on GLP-1; however, this
phenomenon was observed only in the patient in case 1,
but not in the other subjects. These latter findings can
also be partly explained by an induced decrease in blood
glucose levels. In support of this hypothesis, Aoki et al.
reported that sitagliptin decreased the AUC of blood
glucose levels without increasing insulin levels in sub-
jects without diabetes [27]. They also described that this
effect may be explained by a decrease in plasma gluca-
gon levels [14,28]. The glucose-lowering effect of GLP-1
is based not only on its potent insulinotropic action, but
also on its ability to restrain glucagon secretion. To
date, it is unknown whether GLP-1 directly suppresses
glucagon release by binding to GLP-1 receptors
expressed on the alpha cell, or indirectly by modulating
the release of secretory products, such as insulin [29],
somatostatin [30-32], or others, from the beta or delta
cells. In our subjects, the decrease in glucagon levels
was not remarkable even after sitagliptin administration,
which enhances GLP-1 secretion. Although GLP-1 is a
powerful suppressor of glucagon secretion, the decrease
in glucose levels should result in increased glucagon
secretion, and the balance of these phenomena may lead
to different degrees of changes in glucagon secretion. As
discussed above, miglitol has been reported to enhance
GLP-1 release. However, this was observed only in the
patient in case 3 and the control subject, but not in the
patients in cases 1 and 2. After sitagliptin was coadmi-
nistered with miglitol, all the subjects showed incremen-
tal increases in GLP-1 levels, as expected, with different
magnitudes. A recent report indicated that once-daily
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D E F 
Figure 2 Time course of CGM measured glucose (A), insulin (B), I/G(insulin to CGM measured glucose ratio) (C), glucagon (D), active
GLP-1 (E), and GIP (F) levels before and after meal intake in the patient in case 1. The clear squares indicate no medication, filled squares
indicate miglitol administration, and filled triangles indicate coadministration of miglitol and sitagliptin.
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Figure 3 Time course of CGM measured glucose (A), insulin (B), I/G(insulin to CGM measured glucose ratio) (C), glucagon (D), active
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0 30 60 120 180 240 
Figure 4 Time course of CGM measured glucose (A), insulin (B), I/G(insulin to CGM measured glucose ratio) (C), glucagon (D), active
GLP-1 (E), and GIP (F) levels before and after meal intake in the patient in case 3.
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no medication miglitol miglitol + sitagliptin 
Figure 5 Time course of CGM measured glucose (A), insulin (B), I/G(insulin to CGM measured glucose ratio) (C), glucagon (D), active
GLP-1 (E), and GIP (F) levels before and after meal intake in the patient in the control subject.
Table 3 Area under the curve (AUC) values during the 4-h meal test
Case 1 Case 2 Case 3 Control
Glucose (CGM) AUC (103 ×mg/dl·4 h)
no medication 36.4 55.8 45.4 18.8
miglitol 34.6 53.6 34.9 22.6
miglitol + sitagliptin 30.2 40.1 39.0 20.3
Insulin AUC (103 × pmol/l·4 h)
no medication 35.7 83.8 68.0 28.1
miglitol 23.1 49.3 60.9 20.1
miglitol + sitagliptin 36.7 57.6 56.5 16.2
Glucagon AUC (103 × ng/l·4 h)
no medication 30.5 24.6 18.1 26.4
miglitol 33.4 24.8 20.1 25.2
miglitol + sitagliptin 34.1 23.1 18.2 25.2
GLP-1 (active) (103 × pmol/l·4 h)
no medication 0.3 1.1 1.7 2.5
miglitol 0.5 0.7 3.2 3.2
miglitol+sitagliptin 5.0 2.8 4.4 7.3
GIP (total) (103 × pmol/L·4 h)
no medication 15.1 18.0 13.7 27.1
miglitol 8.3 9.4 15.4 15.5
miglitol + sitagliptin 7.6 11.1 8.9 12.6
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AUC of active plasma GLP-1 levels even after lunch in
sitagliptin-treated patients with type 2 diabetes [33].
Several studies have shown that patients with type 2 dia-
betes generally exhibit attenuated GLP-1 secretion
[34-37], although others have reported normal GLP-1
secretion in these patients [38,39]. In our patients, GLP-
1 secretion was preserved and enhanced by administra-
tion of the DPP-4 inhibitor, but whether the levels of
GLP-1 secretion were sufficient could not be deter-
mined. Future studies with larger numbers of patients
will be required to investigate the clinical characteristics
of patients who show a better GLP-1 response to sita-
gliptin (sitagliptin responders) and who are more likely
to benefit from the treatments with the agents adminis-
tered in this study. When miglitol is administered, the
total GIP level is considered to decrease via an inhibi-
tion of glucose absorption in the upper intestine [15];
this tendency was also confirmed after 12-week adminis-
tration of miglitol [18]. Our results, with the exception
of 1 patient, are consistent with this theory. Among the
subjects in this study, 1 patient and the control subject
showed a remarkable decrease in GIP levels after the
addition of sitagliptin, compared to miglitol administra-
tion alone, while the other subjects did not exhibit any
change in GIP levels. Sitagliptin is reported to decrease
the total GIP level [28], but this may not be applicable
to all patients with type 2 diabetes. However, we can
conclude that compared to no medication, all the sub-
jects showed suppressed GIP levels when miglitol and
sitagliptin were coadministered.
In conclusion, using CGMS, we revealed that a combi-
nation of the a-GI, miglitol, and the DPP-4 inhibitor
sitagliptin was effective in reducing glucose fluctuation
and stabilizing postprandial blood glucose levels. A lim-
itation of this study is the small number of subjects
examined. For this reason, we cannot apply our results
to the general population of type 2 diabetes patients.
Our results do show completely different patterns of
insulin, glucagon, GLP-1, and GIP responses to the
study medications, suggesting that hormonal responses
to the a-GI and DPP-4 inhibitors differ among indivi-
duals, and that these responses may be complicated by
multifactorial effects. Differences in hormonal responses
to the drugs may partly be explained by differences in
the duration of diabetes and pretreatment medication of
our subjects. Further studies are needed to determine
which other drugs would act in concert with DPP-4
inhibitors to effectively control postprandial hyperglyce-
mia. Results from these additional studies would be of
great interest in clinical practice.
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